Marksans Pharma Ltd.'s wholly owned subsidiary Relonchem Ltd. has received marketing authorisation for two products from the UK regulator, the Medicines and Healthcare Products Regulatory Agency.
On Tuesday, the company declared to exchanges that it had been granted approval for marketing its Rasagiline Relonchem and Olmesartan film-coated tablets.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
These tablets will be sold as Rasagiline Relonchem 1 mg, Olmesartan 10 mg, Olmesartan 20 mg and Olmesartan 40 mg.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
Rasagiline and olmesartan are drugs that are used to treat Parkinson's disease and hypertension, respectively.
Marksans Pharma shares were trading higher after the UK MHRA granted marketing authorisation for four products to its subsidiary.
The company's stock rose as much as 3.07% during the day to Rs 168.80 apiece on the NSE. It was trading 1.66% higher at Rs 166.34 apiece, as compared to a 0.01% decline in the benchmark NSE Nifty 50 as of 2:50 p.m.
It has risen 79.27% in the last 12 months and 3.35% on a year-to-date basis. The total traded volume so far in the day stood at 1.7 times its 30-day average. The relative strength index was at 58.42.
Four analysts tracking the company have a 'buy' rating on the stock, according to Bloomberg data. The average of 12-month analyst price targets implies a potential upside of 19.4%.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
